CN101623317B - Serrate club moss oral disintegrating tablet and preparation method thereof - Google Patents
Serrate club moss oral disintegrating tablet and preparation method thereof Download PDFInfo
- Publication number
- CN101623317B CN101623317B CN 200810129659 CN200810129659A CN101623317B CN 101623317 B CN101623317 B CN 101623317B CN 200810129659 CN200810129659 CN 200810129659 CN 200810129659 A CN200810129659 A CN 200810129659A CN 101623317 B CN101623317 B CN 101623317B
- Authority
- CN
- China
- Prior art keywords
- serrate
- add
- huperzine
- disintegrating tablet
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001504070 Huperzia Species 0.000 title claims abstract description 17
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 title claims abstract description 17
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000003756 stirring Methods 0.000 claims abstract description 14
- 238000001035 drying Methods 0.000 claims abstract description 11
- 239000007962 solid dispersion Substances 0.000 claims abstract description 8
- 239000000758 substrate Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 claims description 21
- 239000002671 adjuvant Substances 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 239000006185 dispersion Substances 0.000 claims description 10
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
- 238000004132 cross linking Methods 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 9
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 9
- 239000012467 final product Substances 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 235000009508 confectionery Nutrition 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- -1 polyoxyethylene stearate Polymers 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 3
- 125000004185 ester group Chemical group 0.000 claims 1
- 239000008187 granular material Substances 0.000 abstract description 9
- 239000002904 solvent Substances 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 239000000284 extract Substances 0.000 abstract description 2
- 239000000314 lubricant Substances 0.000 abstract description 2
- 239000007767 bonding agent Substances 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 23
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 14
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 14
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 14
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- UBAPRWGDQPSCEH-UHFFFAOYSA-N Des-N-methyl-beta-obscurine Natural products N1CCCC2C3CC(C)CC21C(C=CC(=O)N1)=C1C3 UBAPRWGDQPSCEH-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- YYWGABLTRMRUIT-XHBSWPGZSA-N Huperzine B Natural products N1CCC[C@@H]2[C@@H]3C=C(C)C[C@]21C(C=CC(=O)N1)=C1C3 YYWGABLTRMRUIT-XHBSWPGZSA-N 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001090156 Huperzia serrata Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Abstract
The invention relates to a serrate club moss oral disintegrating tablet and a preparation method thereof. The method comprises the following steps: dissolving serrate club moss extract in a proper solvent; preparing a solid dispersion through dispersively spraying the mixture in an auxiliary material or dripping the mixture in a fused substrate; crushing the solid dispersion; adding the substance into the auxiliary material; stirring the mixture evenly; adding a bonding agent into the mixture for granulating; drying the granulates; adding lubricant into the granulates; and tabletting the granulates.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of serrate club moss oral disintegrating tablet and manufacture method thereof.
Background technology
Huperzine Serrate P.E is from China's Chinese herbal medicine Huperziaceae plant Herba Lycopodii serrati (Chinese herbal and crude drugs preparations that extracts the plant such as Huperzia serrata (Thunb.) Trev, mainly contain huperzine A, huperzine B, the ingredients such as flavone, and wherein huperzine A is a kind of efficient, the intracerebroventricuacetylcholine acetylcholine esterase inhibitor of high selectivity, true acetylcholine esterase had selective inhibitory, easily pass through blood brain barrier, long action time, has the promotion memory represents, the effect that hypermnesis keeps, China medicine worker in 1970 inhibitory action of Huperziaceae plant to acetylcholine esterase that begin one's study, the bright grade of Tang Xi in 1986 huperzine A of reporting for work first is improved the effect of learning and memory in rats, nineteen ninety-five the domestic huperzine A tablet of at first developing, be applied to treat senile dementia, the diseases such as benign memory deficits, huperzine B also have the pharmacological action of similar huperzine A.Clinical evaluation shows: compare with similar drugs, huperzine A has rapid-action, easily sees through blood brain barrier, and long action time can make things convenient for the advantages such as oral application.Existing market is sold and to be mainly contained huperzine A tablet, capsule, because huperzine A is water insoluble, has and draws moistly, and principal agent dosage is few, uses comminution by gas stream or the equivalent legal system of progressively increasing standby when the Huperzine-A Tablets, Tests for Uniformity of traditional method preparation and capsule.Have in the market medicine and healthcare food preparation now, also do not contain the Chinese medicine preparation that preparation, particularly oral cavity disintegration tablet are this efficiently, bioavailability is high of the pure Chinese herbal medicine of huperzine A, huperzine B.The exploitation serrate club moss oral disintegrating tablet has widely practical value
The present invention makes serrate club moss oral disintegrating tablet by solvent-applied dispersion and solid dispersion technology, correct and overcome some defectives when making huperzine A orally disintegrating tablets agent, capsule, serrate club moss oral disintegrating tablet volume of the present invention is little, can be oral, need not water delivery service, great convenience is provided particularly for child and elderly patients, the serrate club moss oral disintegrating tablet of using the present invention's preparation has efficiently, reaches the high characteristics of bioavailability.
Summary of the invention
The present invention is logical to be that solvent-applied dispersion method and solid dispersion technology are made serrate club moss oral disintegrating tablet, had even release, and dissolution and dissolution rate are stable, the steady quality characteristics.Because serrate club moss oral disintegrating tablet agent volume is little, easy to carry and use, can be oral, and this oral cavity disintegration tablet bioavailability is high.With the common huperzine A orally disintegrating tablets agent of manufacturing, capsule, oral cavity disintegration tablet supplementary product consumption of the present invention is few, need not complicated, the expensive device such as micronization relatively, working condition and production equipment are simple, reduce and pollute, and reduce labor intensity, reduce production costs, show characteristics of the present invention.
The selected adjuvant of the present invention all meets the pharmaceutic adjuvant of medicinal requirements, sum up by lot of experiments, obtain a result, this drug component forms and comprises: Huperzine Serrate P.E, appropriate amount of auxiliary materials, wherein adjuvant comprises the fillibility adjuvant and has the plasticity adjuvant, and the fillibility adjuvant has cross-linking sodium carboxymethyl cellulose, polyethylene glycol 6000, Macrogol 4000, polyoxyethylene stearate (40) ester, polyoxyethylene sorbitan monoleate, xylitol, mannitol, lactose, sucrose, microcrystalline Cellulose, Pulvis Talci, sodium bicarbonate, calcium hydrogen phosphate, magnesium stearate, aluminium stearate, sodium stearate, insect wax, Cera Flava, stearyl alcohol, spermol, hydroxypropyl emthylcellulose (HPMC), hydroxyethyl-cellulose (HEC), HPMC (HPC-Na), ethyl cellulose, polyvinylpyrrolidone and A Siba are sweet.The plasticity adjuvant has gelatin, Resina persicae, arabic gum, corn starch, dextrin, alginic acid, glucosamine.
Best substrate adjuvant of the present invention is that cross-linking sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose (HPMC), ethyl cellulose (HEC), HPMC (HPC-Na), microcrystalline Cellulose are 0.3 with the ratio of the weight of lactose, mannitol: 1-0.5: 1.Xylitol is 1 with the ratio of the weight of starch: 0.3-1: 0.5, or the ratio of sorbitol and the weight of starch is 1: 0.2-1: 0.5.Huperzine Serrate P.E is 1 with the ratio of the weight of adjuvant in the pharmaceutical composition of the present invention: 20-1: 800.
Preferred pharmaceutical composition Chinese medicine of the present invention is 1 with the ratio of adjuvant: 60-1: 700.
Best pharmaceutical composition Chinese medicine of the present invention is 1 with the ratio of adjuvant: 80-1: 600.
The content of preparation of Chinese medicine of the present invention calculates with huperzine A, is 0.03-1% (weight ratio), or 50-1000 μ g/ sheet.
The ratio of the adjuvant of pharmaceutical composition of the present invention and the consumption of medicine all is in pharmaceutics and the pharmacopeia allowed band, feeds intake by metering, makes the huperzine A content in every oral cavity disintegration tablet serrate club moss oral disintegrating tablet reach the requirement (50 μ g-800 μ g/ sheet) that pharmacopeia is stipulated.The prepared serrate club moss oral disintegrating tablet of the present invention has easy, the steady quality of preparation, and clinical administration is convenient, characteristics that can be oral.
The present invention is based on dissolution with solvents method and solid dispersion law technology, A: with 1 weight portion Huperzine Serrate P.E and 20 to 100 parts by weight solvent through being dissolved into homogeneous solution, add proper amount of surfactant, join in the substrate of 60 to 800 weight portions by the phase process for dispersing that disperses spray to add, stir, after the interpolation lubricant stirs, direct compression, drying is made serrate club moss oral disintegrating tablet.B: or granulate in granulator by wet granulation process, drying is mixed, tabletting, and drying is made serrate club moss oral disintegrating tablet.C: or with 1 weight portion Huperzine Serrate P.E and 20 to 100 parts by weight solvent through being dissolved into homogeneous solution, add proper amount of surfactant, stir; add in the substrate that melting stirs, stir, cooling; pulverize, become the Herba Lycopodii serrati solid dispersion, add an amount of adjuvant; mix homogeneously, direct compression or in granulator, granulate drying by wet granulation process; mix; tabletting, drying is made serrate club moss oral disintegrating tablet.
Specific implementation method
One, example 1
Make 1000 oral cavity disintegration tablets
Method for making: Huperzine Serrate P.E is dissolved in fully dissolving in the ethanol, add polyoxyethylene sorbitan monoleate, stir, become the dispersion ethanol of Huperzine Serrate P.E, spray adds in the adjuvant of cross-linking sodium carboxymethyl cellulose, methylcellulose, citric acid, mannitol and the sweet composition of A Siba of mix homogeneously, is stirred well to evenly, adds the magnesium stearate mix homogeneously, tabletting, and get final product.
Two, example 2
Prescription:
Make 1000
Method for making: Huperzine Serrate P.E is dissolved in the ethanol.Fully dissolving, add polyoxyethylene sorbitan monoleate, stir, become the dispersion ethanol of Huperzine Serrate P.E, spray adds in the adjuvant of cross-linking sodium carboxymethyl cellulose, micropowder silica gel, polyvinylpyrrolidone and the sweet composition of A Siba of mix homogeneously, is stirred well to evenly, adds the magnesium stearate mix homogeneously, direct compression, and get final product.
Three, example 3,
Prescription
Make 1000
Method for making: Huperzine Serrate P.E is dissolved in fully dissolving in the ethanol, add polyoxyethylene sorbitan monoleate, stir, become the dispersion ethanol of Huperzine Serrate P.E, add in the adjuvant of cross-linking sodium carboxymethyl cellulose, micropowder silica gel, mannitol, lactose and the sweet composition of A Siba of mix homogeneously, be stirred well to evenly, add again the magnesium stearate mix homogeneously, tabletting, drying, and get final product.
Four, example 4
Prescription
Make 1000
Method for making: Huperzine Serrate P.E is dissolved in the ethanol, fully dissolving, add polyoxyethylene sorbitan monoleate, stir, become the dispersion ethanol of Huperzine Serrate P.E, add the Macrogol 4000, polyoxyethylene stearate of 80 ℃ of lower meltings { in the substrate that the 40} ester forms, be stirred well to evenly, cooling becomes the Herba Lycopodii serrati solid dispersion, pulverize and add in the adjuvant of cross-linking sodium carboxymethyl cellulose, lactose and the sweet composition of A Siba of mix homogeneously, be stirred well to evenly, add the magnesium stearate mix homogeneously, tabletting, drying, and get final product.
Five, example 5,
Prescription
Make 1000
Method for making: Huperzine Serrate P.E is dissolved in fully dissolving in the ethanol, add polyoxyethylene sorbitan monoleate, stir, become the dispersion ethanol of Huperzine Serrate P.E, add in the adjuvant that cross-linking sodium carboxymethyl cellulose, micropowder silica gel, citric acid and the mannitol of mix homogeneously have formed, be stirred well to evenly, add the magnesium stearate mix homogeneously, tabletting, drying, and get final product.
Six, example 6,
Prescription:
Make 1000 oral cavity disintegration tablets
Press oral cavity disintegration tablet, coating, method for making: Huperzine Serrate P.E is dissolved in the ethanol.Fully dissolving, add polyoxyethylene sorbitan monoleate, stir, become the dispersion ethanol of Huperzine Serrate P.E, spray adds hydroxypropyl cellulose, citric acid, micropowder silica gel, mannitol, the lactose of mix homogeneously, be stirred well to evenly, granulate with the polyvinylpyrrolidone alcoholic solution, 60 ℃ lower dry, granulate, add the magnesium stearate mix homogeneously, tabletting, and get final product.
Seven, example 7
Prescription:
Make 1000
Method for making: Huperzine Serrate P.E is dissolved in the ethanol.Fully dissolving adds polyoxyethylene sorbitan monoleate, stirs, become the dispersion ethanol of Huperzine Serrate P.E, spray add cross-linking sodium carboxymethyl cellulose, citric acid, lactose, mannitol, the A Siba of mix homogeneously sweet in, be stirred well to evenly, granulate with the polyvinylpyrrolidone alcoholic solution, 60 ℃ lower dry, granulate adds the magnesium stearate mix homogeneously, tabletting, drying, and get final product.
Claims (1)
1. a serrate club moss oral disintegrating tablet is characterized in that, its composition and preparation method are as follows:
Make 1000
Method for making: Huperzine Serrate P.E is dissolved in the ethanol, fully dissolving, add polyoxyethylene sorbitan monoleate, stir, become the dispersion ethanol of Huperzine Serrate P.E, add in Macrogol 4000 80 ℃ of lower meltings, the substrate that polyoxyethylene stearate (40) ester forms, be stirred well to evenly, cooling becomes the Herba Lycopodii serrati solid dispersion, pulverize and add in the adjuvant of cross-linking sodium carboxymethyl cellulose, lactose and the sweet composition of A Siba of mix homogeneously, be stirred well to evenly, add the magnesium stearate mix homogeneously, tabletting, drying, and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810129659 CN101623317B (en) | 2008-07-07 | 2008-08-05 | Serrate club moss oral disintegrating tablet and preparation method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810137881.6 | 2008-07-07 | ||
| CN200810137881 | 2008-07-07 | ||
| CN 200810129659 CN101623317B (en) | 2008-07-07 | 2008-08-05 | Serrate club moss oral disintegrating tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101623317A CN101623317A (en) | 2010-01-13 |
| CN101623317B true CN101623317B (en) | 2013-03-06 |
Family
ID=41519412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810129659 Active CN101623317B (en) | 2008-07-07 | 2008-08-05 | Serrate club moss oral disintegrating tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101623317B (en) |
-
2008
- 2008-08-05 CN CN 200810129659 patent/CN101623317B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101623317A (en) | 2010-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101708336B (en) | Novel medicinal premixing auxiliary material | |
| CN114129527B (en) | Miniature tablet and preparation method and preparation thereof | |
| CN105935358B (en) | One seed sand library is than bent Valsartan sustained release agent and preparation method thereof | |
| CN101816637B (en) | Leflunomide tablet preparation and preparation method thereof | |
| WO2019024949A1 (en) | Manufacturing method of oral dosage form containing berberine, oral dosage form containing berberine and use thereof | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN107913256A (en) | A kind of macitentan oral disnitegration tablet for treating pulmonary hypertension and preparation method thereof | |
| CN106667936A (en) | Sofosbuvir tablet and preparation method thereof | |
| CN101804084B (en) | Solid dispersion and preparation method thereof | |
| CN101623317B (en) | Serrate club moss oral disintegrating tablet and preparation method thereof | |
| CA2492156C (en) | Tablet composition containing kampo medicinal extract and its manufacturing process | |
| CN103655512B (en) | Vaginal fenticonazole nitrate soft capsule and preparation method thereof | |
| CN101804038A (en) | Huperzine A preparation for treating schizophrenia and nervous function damage and preparation method thereof | |
| CN102824644B (en) | High-stability sustained-release tablet prepared by using hydroxy propyl cellulose | |
| CN101658544B (en) | Controlled release tablets of huperzia serrata and method for preparing same | |
| CN101785762B (en) | Huperzine A orally disintegrating tablets and preparation method thereof | |
| CN101991859A (en) | Beta-cyclodextrin inclusion compound of huperzine A, and preparation method and preparation thereof | |
| CN110354093A (en) | A kind of mosapride citrate pharmaceutical composition | |
| KR100735904B1 (en) | Tablet composition containing extract of natural herbal plants and its manufacturing process | |
| CN103768060B (en) | Compound tablet of ibuprofen, pseudoephedrine hydrochloride and chlorpheniramine maleate | |
| CN101658543A (en) | Huperzia serrata tablets and method for preparing same | |
| CN101890057A (en) | Herba Pteridis Multifidae preparation that treatment gastrointestinal tract, urinary tract infection and the heart, cerebrovascular disease are used and preparation method thereof | |
| TWI734247B (en) | Cellulose composition and lozenge | |
| TWI723621B (en) | Cellulose composition, lozenge and orally disintegrating tablet | |
| CN100415269C (en) | Method for preparing cow-bezoar snake bile Sichuan fritillary bulb dispersive tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG WORLDBEST PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XIE JINSHENG Effective date: 20100915 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 317500 NO.133, WANSHOU ROAD, TAIPING STREET, WENLING CITY, ZHEJIANG PROVINCE TO: 317500 NO.28, BAIZHANG NORTH ROAD, CHENGDONG STREET, WENLING CITY, ZHEJIANG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20100915 Address after: 317500 east of Zhejiang province Wenling city streets Baizhang Road No. 28 Applicant after: Zhejiang Worldbest Pharmaceutical Co., Ltd. Address before: 317500 No. 133 Taiping Street, Zhejiang, Wanshou Road, Wenling Applicant before: Xie Jinsheng |
|
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 317500 east of Zhejiang province Wenling city streets Baizhang Road No. 28 Applicant after: Zhejiang Wanbang Pharmaceutical Co., Ltd. Address before: 317500 east of Zhejiang province Wenling city streets Baizhang Road No. 28 Applicant before: Zhejiang Worldbest Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ZHEJIANG WORLDBEST PHARMACEUTICAL CO., LTD. TO: ZHEJIANG WANBANG PHARMACEUTICAL CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: WANBANGDE PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: ZHEJIANG WANBANG PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 317500 east of Zhejiang province Wenling city streets Baizhang Road No. 28 Patentee after: WANBANGDE PHARMACEUTICAL GROUP CO., LTD. Address before: 317500 east of Zhejiang province Wenling city streets Baizhang Road No. 28 Patentee before: Zhejiang Wanbang Pharmaceutical Co., Ltd. |
|
| CP03 | Change of name, title or address |
Address after: 317500, Zhejiang Province, Taizhou City, Wenling Province Street 28 North Zhang Road Patentee after: Wanbond Pharmaceutical Group Co., Ltd Address before: 317500, 28 North Road, Chengdong street, Zhejiang, Wenling Patentee before: ZHEJIANG WANBANG PHARMACEUTICAL PLC |
|
| CP03 | Change of name, title or address |